Table 1.

In vitro susceptibilities of 257 clinical yeast isolates to four azole drugsa

Organism (no. of isolates) and antifungal agentMIC (μg/ml)Organism (no. of isolates) and antifungal agentMIC (μg/ml)
Range50%90%Range50%90%
C. albicans (84)
 SCH≤0.0078–>4.00.0150.25
 FLC≤0.125–>640.258.0
 ITC0.03–>4.00.1251.0
 KETO≤0.03–160.061.0
C. tropicalis (20)
 SCH≤0.0078–0.1250.030.06
 FLC0.125–2.00.252.0
 ITC0.06–0.50.250.25
 KETO0.06–0.250.060.125
C. glabrata (15)
 SCH0.015–1.00.251.0
 FLC0.25–8.04.08.0
 ITC0.06–2.00.52.0
 KETO0.125–2.01.02.0
C. parapsilosis (15)
 SCH0.015–0.50.060.25
 FLC0.25–4.01.02.0
 ITC0.25–2.00.250.5
 KETO0.06–2.00.251.0
C. kefyr(14)
 SCH0.015–4.00.1250.5
 FLC≤0.125–160.2516
 ITC0.125–1.00.251.0
 KETO0.06–1.00.060.5
C. krusei(14)
 SCH0.25–>4.00.52.0
 FLC16–>6432>64
 ITC1.0–>4.02.04.0
 KETO0.125–8.04.04.0
C. famata(10)
 SCH0.06–4.00.54.0
 FLC1.0–648.064
 ITC0.125–4.01.04.0
 KETO0.25–160.516
C. guilliermondii (10)
 SCH0.03–0.250.1250.25
 FLC1.0–8.04.08.0
 ITC0.25–1.00.50.5
 KETO0.125–0.50.250.25
C. inconspicua(10)
 SCH0.125–4.00.50.5
 FLC4.0–>641664
 ITC0.25–>4.01.02.0
 KETO0.5–>162.08.0
C. lusitaniae (10)
 SCH≤0.0078–0.060.030.06
 FLC≤0.125–1.00.251.0
 ITC0.06–0.250.1250.25
 KETO≤0.03–0.1250.060.125
C. pelliculosa(10)
 SCH2.02.02.0
 FLC4.0–324.032
 ITC0.5–2.01.02.0
 KETO1.0–2.01.0
C. lipolytica(8)
 SCH0.06–2.01.0
 FLC2.0–>644.0
 ITC0.06–2.01.0
 KETO0.5–8.02.0
S. cerevisiae(15)
 SCH0.015–>4.00.1254.0
 FLC0.25–>644.064
 ITC0.015–>4.00.5>4.0
 KETO0.06–>160.54.0
C. neoformans (15)
 SCH0.015–0.250.1250.25
 FLC0.5–8.04.08.0
 ITC0.03–0.50.250.5
 KETO0.125–1.00.51.0
R. rubra(7)
 SCH2.0–>4.02.0
 FLC64–>64>64
 ITC2.0–>4.0>4.0
 KETO0.5–2.01.0
All organisms (257)
 SCH≤0.0078–>4.00.062.0
 FLC≤0.125–>641.064
 ITC0.015–>4.00.252.0
 KETO≤0.03–>160.1254.0
  • a MICs were determined after 48 h of incubation for all yeasts with the exception of isolates of C. neoformans and R. rubra, for which MICs were determined after 72 h of incubation under the NCCLS conditions (7).